Matrine inhibits ovarian cancer cell viability and promotes apoptosis by regulating the ERK/JNK signaling pathway via p38MAPK

Liang,Xin; Ju,Jianxin

doi:10.3892/or.2021.8033

Matrine inhibits ovarian cancer cell viability and promotes apoptosis by regulating the ERK/JNK signaling pathway via p38MAPK

Authors:
- Xin Liang
- Jianxin Ju
View Affiliations

Affiliations: Discipline Inspection and Supervision Division, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang 157000, P.R. China, Xiangyang Community, Hongqi Hospital Affiliated to Mudanjiang Medical University, Mudanjiang, Heilongjiang 157000, P.R. China
Published online on: March 30, 2021 https://doi.org/10.3892/or.2021.8033
Article Number: 82
Copyright: © Liang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer displays the highest mortality rate among all types of gynecological cancer worldwide. The survival of patients with ovarian cancer remains poor due to poor responses to anticancer treatments. The present study aimed to investigate the therapeutic effects and potential mechanism underlying matrine in ovarian cancer tissues, ovarian cancer cells and a CAOV‑3‑derived tumor‑bearing mouse model. MTT, migration, invasion, flow cytometry, immunofluorescence and immunohistochemistry assays were performed to assess the inhibitory effects of matrine on ovarian cancer. A xenograft ovarian cancer mouse model was established and treated with matrine or PBS. The results demonstrated that compared with the control group, matrine significantly induced ovarian cancer cell apoptosis by upregulating caspase‑8 and Fas cell surface death receptor (Fas) expression levels, and downregulating Bcl‑2 and Bcl‑xl expression levels. Moreover, compared with the control group, matrine significantly inhibited ovarian cancer cell viability, migration and invasion by downregulating metastasis associated protein‑1, fibronectin, angiotensin II type 2 receptor–interacting protein 3a and H high mobility group AT‑hook 2 expression levels. Compared with the control group, matrine significantly increased p38MAPK, phosphorylated (p)ERK/ERK and pJNK/JNK expression levels in ovarian cancer cells. p38MAPK knockdown significantly downregulated p38MAPK, pERK/ERK and pJNK/JNK expression levels compared with the control group, which significantly promoted ovarian cancer cell viability, migration and invasion. In vivo experiments demonstrated that compared with the control group, matrine significantly suppressed tumor growth by markedly upregulating p38MAPK, ERK and JNK expression levels. The immunohistochemistry results demonstrated that caspase‑8 and Fas expression levels were notably increased, whereas Bcl‑2 and Bcl‑xl expression levels were obviously decreased in matrine‑treated tumors compared with PBS‑treated tumors. In conclusion, the present study demonstrated that matrine inhibited ovarian cancer cell viability, migration and invasion, but induced cell apoptosis, suggesting that matrine may serve as a promising anticancer agent for the treatment of ovarian cancer.

View Figures

View References

1	Ahmed-Lecheheb D and Joly F: Ovarian cancer survivors' quality of life: A systematic review. J Cancer Surviv. 10:789–801. 2016. View Article : Google Scholar : PubMed/NCBI
2	Ebell MH, Culp MB and Radke TJ: A systematic review of symptoms for the diagnosis of ovarian cancer. Am J Prev Med. 50:384–394. 2016. View Article : Google Scholar : PubMed/NCBI
3	Alipour S, Zoghi S, Khalili N, Hirbod-Mobarakeh A, Emens LA and Rezaei N: Specific immunotherapy in ovarian cancer: A systematic review. Immunotherapy. 8:1193–1204. 2016. View Article : Google Scholar : PubMed/NCBI
4	Tempfer CB, El Fizazi N, Ergonenc H and Solass W: Metastasis of ovarian cancer to the breast: A report of two cases and a review of the literature. Oncol Lett. 11:4008–4012. 2016. View Article : Google Scholar : PubMed/NCBI
5	Silva C, Caramelo O, Almeida-Santos T and Ribeiro Rama AC: Factors associated with ovarian function recovery after chemotherapy for breast cancer: A systematic review and meta-analysis. Hum Reprod. 31:2737–2749. 2016. View Article : Google Scholar : PubMed/NCBI
6	Wands JR: Prevention of hepatocellular carcinoma. N Engl J Med. 351:1567–1570. 2004. View Article : Google Scholar : PubMed/NCBI
7	Zhang Z, Wang X, Wu W, Wang J, Wang Y, Wu X, Fei X, Li S, Zhang J, Dong P, et al: Effects of matrine on proliferation and apoptosis in gallbladder carcinoma cells (GBC-SD). Phytother Res. 26:932–937. 2012. View Article : Google Scholar : PubMed/NCBI
8	Zhang P, Wang Z, Chong T and Ji Z: Matrine inhibits proliferation and induces apoptosis of the androgenindependent prostate cancer cell line PC-3. Mol Med Rep. 5:783–787. 2012.PubMed/NCBI
9	Tang XB, Shen XH, Li L, Zhang YF and Chen GQ: SOX2 overexpression correlates with poor prognosis in laryngeal squamous cell carcinoma. Auris Nasus Larynx. 40:481–486. 2013. View Article : Google Scholar : PubMed/NCBI
10	Lao Y: Clinical study of matrine injection on preventing liver function damage of anti-tumor drugs during chemotherapy of breast cancer. Zhong Yao Cai. 28:735–737. 2005.(In Chinese). PubMed/NCBI
11	Lao Y: Clinical study on effect of matrine injection to protect the liver function for patients with primary hepatic carcinoma after trans-artery chemo-embolization (TAE)]. Zhong Yao Cai. 28:637–638. 2005.(In Chinese). PubMed/NCBI
12	Chang C, Liu SP, Fang CH, He RS, Wang Z, Zhu YQ and Jiang SW: Effects of matrine on the proliferation of HT29 human colon cancer cells and its antitumor mechanism. Oncol Lett. 6:699–704. 2013. View Article : Google Scholar : PubMed/NCBI
13	Shao H, Yang B, Hu R and Wang Y: Matrine effectively inhibits the proliferation of breast cancer cells through a mechanism related to the NF-kB signaling pathway. Oncol Lett. 6:517–520. 2013. View Article : Google Scholar : PubMed/NCBI
14	Liu Y, Xu Y, Ji W, Li X, Sun B, Gao Q and Su C: Anti-tumor activities of matrine and oxymatrine: Literature review. Tumour Biol. 35:5111–5119. 2014. View Article : Google Scholar : PubMed/NCBI
15	Shibata S, Marushima H, Asakura T, Matsuura T, Eda H, Aoki K, Matsudaira H, Ueda K and Ohkawa K: Three-dimensional culture using a radial flow bioreactor induces matrix metalloprotease 7-mediated EMT-like process in tumor cells via TGFbeta1/Smad pathway. Int J Oncol. 34:1433–1448. 2009.PubMed/NCBI
16	Deschenes-Simard X, Gaumont-Leclerc MF, Bourdeau V, Lessard F, Moiseeva O, Forest V, Igelmann S, Mallette FA, Saba-El-Leil MK, Meloche S, et al: Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev. 27:900–915. 2013. View Article : Google Scholar : PubMed/NCBI
17	Echevarria-Vargas IM, Valiyeva F and Vivas-Mejia PE: Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway. PLoS One. 9:e970942014. View Article : Google Scholar : PubMed/NCBI
18	Sheppard KE, Cullinane C, Hannan KM, Wall M, Chan J, Barber F, Foo J, Cameron D, Neilsen A, Ng P, et al: Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. Eur J Cancer. 49:3936–3944. 2013. View Article : Google Scholar : PubMed/NCBI
19	Liu HZ, Yu C, Yang Z, He JL, Chen WJ, Yin J, Li WM, Liu HT and Wang YX: Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways. Mol Med Rep. 4:985–992. 2011.PubMed/NCBI
20	Zhao T, Ding X, Chang B, Zhou X and Wang A: MTUS1/ATIP3a down-regulation is associated with enhanced migration, invasion and poor prognosis in salivary adenoid cystic carcinoma. BMC Cancer. 15:2032015. View Article : Google Scholar : PubMed/NCBI
21	Molina A, Velot L, Ghouinem L, Abdelkarim M, Bouchet BP, Luissint AC, Bouhlel I, Morel M, Sapharikas E, Di Tommaso A, et al: ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer cell migration and slows metastatic progression by regulating microtubule dynamics. Cancer Res. 73:2905–2915. 2013. View Article : Google Scholar : PubMed/NCBI
22	Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schäfer R and Tchernitsa O: HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer. 123:348–356. 2008. View Article : Google Scholar : PubMed/NCBI
23	Kumar R: Functions and clinical relevance of MTA proteins in human cancer. Preface. Cancer Metastasis Rev. 33:8352014. View Article : Google Scholar : PubMed/NCBI
24	Levenson AS, Kumar A and Zhang X: MTA family of proteins in prostate cancer: Biology, significance, and therapeutic opportunities. Cancer Metastasis Rev. 33:929–942. 2014. View Article : Google Scholar : PubMed/NCBI
25	Tuncay Cagatay S, Cimen I, Savas B and Banerjee S: MTA-1 expression is associated with metastasis and epithelial to mesenchymal transition in colorectal cancer cells. Tumour Biol. 34:1189–1204. 2013. View Article : Google Scholar : PubMed/NCBI
26	Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, Ladanyi A, Penicka CV, George J, Matlin K, et al: Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest. 124:4614–4628. 2014. View Article : Google Scholar : PubMed/NCBI
27	Yousif NG: Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK-PI3K/Akt pathway. Cell Biol Int. 38:85–91. 2014. View Article : Google Scholar : PubMed/NCBI
28	Rong B, Zhao C, Gao W and Yang S: Matrine promotes the efficacy and safety of platinum-based doublet chemotherapy for advanced non-small cell lung cancer. Int J Clin Exp Med. 8:14701–14717. 2015.PubMed/NCBI
29	Yoshikawa N, Kajiyama H, Nakamura K, Utsumi F, Niimi K, Mitsui H, Sekiya R, Suzuki S, Shibata K, Callen D and Kikkawa F: PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells. Oncol Rep. 35:2543–2552. 2016. View Article : Google Scholar : PubMed/NCBI
30	Nordin N, Fadaeinasab M, Mohan S, Hashim NM, Othman R, Karimian H, Iman V, Ramli N, Ali HM and Majid NA: Pulchrin A, a new natural coumarin derivative of enicosanthellum pulchrum, induces apoptosis in ovarian cancer cells via intrinsic pathway. PLoS One. 11:e01540232016. View Article : Google Scholar : PubMed/NCBI
31	Kim M, Hernandez L and Annunziata CM: Caspase 8 expression may determine the survival of women with ovarian cancer. Cell Death Dis. 7:e20452016. View Article : Google Scholar : PubMed/NCBI
32	Maurmann L, Belkacemi L, Adams NR, Majmudar PM, Moghaddas S and Bose RN: A novel cisplatin mediated apoptosis pathway is associated with acid sphingomyelinase and FAS proapoptotic protein activation in ovarian cancer. Apoptosis. 20:960–974. 2015. View Article : Google Scholar : PubMed/NCBI
33	Cohen M, Pierredon S, Wuillemin C, Delie F and Petignat P: Acellular fraction of ovarian cancer ascites induce apoptosis by activating JNK and inducing BRCA1, Fas and FasL expression in ovarian cancer cells. Oncoscience. 1:262–271. 2014. View Article : Google Scholar : PubMed/NCBI
34	Shijo M, Fukase K, Ohtsuka H, Ariake K, Masuda K, Ishida M, Mizuma M, Nakagawa K, Hayashi H, Morikawa T, et al: Metastasis of ovarian cancer to the bile duct: A case report. Surg Case Rep. 5:1002019. View Article : Google Scholar : PubMed/NCBI
35	Yang QY, Li JH, Wang QY, Wu Y, Qin JL, Cheng JJ and Qiu J: MTA1 promotes cell proliferation via DNA damage repair in epithelial ovarian cancer. Genet Mol Res. 13:10269–10278. 2014. View Article : Google Scholar : PubMed/NCBI
36	Carduner L, Agniel R, Kellouche S, Picot CR, Blanc-Fournier C, Leroy-Dudal J and Carreiras F: Ovarian cancer ascites-derived vitronectin and fibronectin: Combined purification, molecular features and effects on cell response. Biochim Biophys Acta. 1830:4885–4897. 2013. View Article : Google Scholar : PubMed/NCBI
37	Califano D, Pignata S, Losito NS, Ottaiano A, Greggi S, De Simone V, Cecere S, Aiello C, Esposito F, Fusco A and Chiappetta G: High HMGA2 expression and high body mass index negatively affect the prognosis of patients with ovarian cancer. J Cell Physiol. 229:53–59. 2014.PubMed/NCBI
38	Zhao T, He Q, Liu Z, Ding X, Zhou X and Wang A: Angiotensin II type 2 receptor-interacting protein 3a suppresses proliferation, migration and invasion in tongue squamous cell carcinoma via the extracellular signal-regulated kinase-Snai2 pathway. Oncol Lett. 11:340–344. 2016. View Article : Google Scholar : PubMed/NCBI
39	Wu J, Sun Y, Zhang PY, Qian M, Zhang H, Chen X, Ma D, Xu Y, Chen X and Tang KF: The Fra-1-miR-134-SDS22 feedback loop amplifies ERK/JNK signaling and reduces chemosensitivity in ovarian cancer cells. Cell Death Dis. 7:e23842016. View Article : Google Scholar : PubMed/NCBI
40	Ptak A and Gregoraszczuk EL: Bisphenol A induces leptin receptor expression, creating more binding sites for leptin, and activates the JAK/Stat, MAPK/ERK and PI3K/Akt signalling pathways in human ovarian cancer cell. Toxicol Lett. 210:332–337. 2012. View Article : Google Scholar : PubMed/NCBI
41	Ohta T, Isobe M, Takahashi T, Saitoh-Sekiguchi M, Motoyama T and Kurachi H: The Akt and ERK activation by platinum-based chemotherapy in ovarian cancer is associated with favorable patient outcome. Anticancer Res. 29:4639–4647. 2009.PubMed/NCBI